CCDC166

Across TCGA pan-cancer cohorts, CCDC166 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CCDC166 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher CCDC166 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCDC166 expression acts as an unfavorable survival marker.

DLBC, SCLC, and LIHC are the cancer types where CCDC166 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
SCLC	DFS	Median	II,III,IV	0.137	0.602	.008	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CCDC166–DLBC (OS)

Open the DLBC breakdown →